<p><strong>250 万美元的预付款，若完全行使短期认股权证，最多可获得 460 万美元的潜在总收入</strong></p>
<p>, /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP)（&#34;我们&#34;或&#34;Acurx&#34;或&#34;公司&#34;），是一家处于后期阶段的生物制药公司，专注于开发新型抗生素以治疗难以治疗的细菌感染，今天宣布完成其之前宣布的 825,085 股普通股（或预先融资认股权证）注册直接发行，购买价格为每股 3.03 美元（或预先融资认股权证），根据纳斯达克规则以市场价格定价。此外，在同时进行的私募中，公司发行了未注册的短期认股权证，最多可购买 1,650,170 股普通股。短期认股权证的行使价格为每股 2.78 美元，发行后立即可行使，并将在注册声明生效后 24 个月到期，该注册声明登记了短期认股权证所对应的普通股的转售。</p>
<p>H.C. Wainwright &amp; Co. 担任此次发行的独家配售代理。</p>
<p>此次发行公司获得的总收入约为 250 万美元，未扣除配售代理费用和公司需支付的其他发行费用。如果未注册的短期认股权证完全按现金方式行使，公司可能获得的额外总收入约为 460 万美元。无法保证这些短期认股权证会被行使。公司目前打算将此次发行的净收入用于营运资金和其他一般企业用途。</p>
<p>普通股（或预先融资认股权证）（但不包括在私募中发行的短期认股权证或其所对应的普通股）是根据公司于 2025 年 7 月 9 日向证券交易委员会（&#34;SEC&#34;）提交的&#34;货架&#34;注册声明（文件编号：333-288595）进行发行，并于 2026 年 1 月 6 日生效。普通股（或预先融资认股权证）的注册直接发行仅通过招股说明书进行，包括构成有效注册声明一部分的招股说明书补充。与注册直接发行相关的招股说明书补充及随附的招股说明书已向 SEC 提交，并可在 SEC 网站 www.sec.gov 上获取。与注册直接发行相关的招股说明书补充及随附的招股说明书的电子副本也可通过联系 H.C. Wainwright &amp; Co., LLC，地址为 430 Park Avenue, 3rd Floor, New York, NY 10022，电话 (212) 856-5711 或电子邮件 placements@hcwco.com 获取。</p>
<p>上述短期认股权证是在根据 1933 年证券法（&#34;证券法&#34;）第 4(a)(2) 条及其下的 D 条款进行的同时私募中发行的，并且与短期认股权证所对应的普通股一起，未根据证券法或适用的州证券法进行注册。因此，短期认股权证及其所对应的普通股在美国不得提供或出售，除非根据有效的注册声明或适用的证券法的注册要求的豁免。</p>
<p>本新闻稿不构成出售或招揽购买此处描述的任何证券的要约，也不应在任何州或司法管辖区进行这些证券的销售，除非在任何此类州或司法管辖区的证券法下进行注册或资格认证。</p>
<p><strong>关于 Acurx Pharmaceuticals, Inc.</strong></p>
<p>Acurx Pharmaceuticals 是一家处于后期阶段的生物制药公司，专注于开发新型小分子抗生素以治疗难以治疗的细菌感染。公司的方法是开发具有革兰氏阳性选择性谱（GPSS®）的抗生素候选药物，阻断革兰氏阳性特异性细菌酶 DNA 聚合酶 IIIC（pol IIIC）的活性位点，抑制 DNA 复制并导致革兰氏阳性细菌细胞死亡。其研发管线包括针对革兰氏阳性细菌的抗生素产品候选药物，包括艰难梭菌、耐甲氧西林金黄色葡萄球菌（MRSA）、耐万古霉素肠球菌（VRE）、耐药性肺炎链球菌（DRSP）和炭疽杆菌（炭疽；生物恐怖主义 A 类威胁级病原体）。</p>
<p>Acurx 的主要产品候选药物 ibezapolstat 用于治疗艰难梭菌感染（CDI），已准备进入第三阶段国际临床试验，前提是获得适当的融资。公司最近宣布启动一项开创性的临床试验，使用 ibezapolstat 治疗多次复发的 CDI（rCDI），这有可能将 rCDI 的治疗和预防范式从两种药物转变为一种药物。该 rCDI 的新临床试验将以开放标签的试点试验开始，以获取在过去 12 个月内至少有 3 次 CDI 发作的多次复发 CDI 患者中使用 IBZ 的经验。这将为计划中的 rCDI 适应症的主动对照第三阶段注册试验提供信息，该试验将在开放标签 20 名患者试验获得良好结果后实施。在随后成功完成 Ph3 关键 rCDI 试验后，根据 FDA 的操作程序，Acurx 计划请求 FDA 批准用于 rCDI 的治疗和预防，依据 FDA 的抗菌和抗真菌药物有限人群途径（行业指南，2020 年）。</p>
<p>公司的临床前管线包括开发一种用于治疗急性细菌性皮肤和皮肤结构感染（ABSSSI）的口服产品候选药物，同时正在计划一项用于治疗吸入性炭疽的开发项目。</p>
<p>要了解更多关于 Acurx Pharmaceuticals 及其产品管线的信息，请访问 www.acurxpharma.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中关于我们未来预期、计划和前景的任何声明，包括关于我们的战略、未来运营、前景、计划和目标的声明，以及包含 “相信”、“预期”、“计划”、“期望” 和类似表达的其他声明，构成 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明。前瞻性声明包括关于在短期认股权证到期前行使的声明以及从发行中获得的收益的使用。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有实质性差异，包括市场和其他条件，以及在公司向证券交易委员会提交的 2025 年 12 月 31 日结束的 10-K 表格年度报告中描述的其他风险和不确定性，以及公司随后向证券交易委员会提交的文件。这些前瞻性声明仅在本新闻稿日期有效，Acurx 不承担更新这些前瞻性声明以反映该声明日期后事件或情况的意图或义务，除非法律要求。</p>
<p><strong>投资者联系：</strong></p>
<p>Acurx Pharmaceuticals, Inc.</p>
<p>David P. Luci，总裁兼首席执行官</p>
<p>电话：917-533-1469</p>
<p>电子邮件：davidluci@acurxpharma.com</p>
<p>来源：Acurx Pharmaceuticals, Inc.</p>

ACXP

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

美国制药 ETF - iShares

纽交所高增长板生物技术指数 ETF - First Trust

<p>Acurx Pharmaceuticals, Inc. 已完成一项注册直接发行，发行了 825,085 股，价格为每股 3.03 美元，筹集了约 250 万美元。公司可能还会通过短期认股权证获得额外的 460 万美元。这些资金将用于营运资金和公司用途。H.C. Wainwright & Co. 担任了本次发行的承销商。此次发行是在与美国证券交易委员会（SEC）签署的货架注册声明下进行的。Acurx 专注于开发针对难治性细菌感染的抗生素，其主要候选药物 ibezapolstat 已准备进入第三阶段临床试验</p>

<p><strong>$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants</strong></p>
<div class="lb-trans"><p><strong>250 万美元的预付款，若完全行使短期认股权证，最多可获得 460 万美元的潜在总收入</strong></p>
</div><p>, /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (&#34;we&#34; or &#34;Acurx&#34; or the &#34;Company&#34;), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the closing of its previously announced registered direct offering of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.03 per share (or pre-funded warrant in lieu thereof) priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued unregistered short-term warrants to purchase up to 1,650,170 shares of common stock. The short-term warrants have an exercise price of $2.78 per share, are immediately exercisable upon issuance and will expire twenty-four months following the effective date of the registration statement registering the resale of the shares of common stock underlying the short-term warrants.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP)（&#34;我们&#34;或&#34;Acurx&#34;或&#34;公司&#34;），是一家处于后期阶段的生物制药公司，专注于开发新型抗生素以治疗难以治疗的细菌感染，今天宣布完成其之前宣布的 825,085 股普通股（或预先融资认股权证）注册直接发行，购买价格为每股 3.03 美元（或预先融资认股权证），根据纳斯达克规则以市场价格定价。此外，在同时进行的私募中，公司发行了未注册的短期认股权证，最多可购买 1,650,170 股普通股。短期认股权证的行使价格为每股 2.78 美元，发行后立即可行使，并将在注册声明生效后 24 个月到期，该注册声明登记了短期认股权证所对应的普通股的转售。</p>
</div><p>H.C. Wainwright &amp; Co. acted as the exclusive placement agent for the offering.</p>
<div class="lb-trans"><p>H.C. Wainwright &amp; Co. 担任此次发行的独家配售代理。</p>
</div><p>The aggregate gross proceeds to the Company from the offering were approximately $2.5 million, before deducting the placement agent fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the unregistered short-term warrants, if fully-exercised on a cash basis, will be approximately $4.6 million. No assurance can be given that any of such short-term warrants will be exercised. The Company currently intends to use the net proceeds from the offering for working capital and other general corporate purposes.</p>
<div class="lb-trans"><p>此次发行公司获得的总收入约为 250 万美元，未扣除配售代理费用和公司需支付的其他发行费用。如果未注册的短期认股权证完全按现金方式行使，公司可能获得的额外总收入约为 460 万美元。无法保证这些短期认股权证会被行使。公司目前打算将此次发行的净收入用于营运资金和其他一般企业用途。</p>
</div><p>The shares of common stock (or pre-funded warrants) (but not the short-term warrants issued in the private placement or the shares of common stock underlying such short-term warrants) were offered by the Company pursuant to a &#34;shelf&#34; registration statement on Form S-3 (File No. 333-288595) filed with the Securities and Exchange Commission (&#34;SEC&#34;) on July 9, 2025, and became effective on January 6, 2026. The registered direct offering of the shares of common stock (or pre-funded warrants) was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to the securities offered in the registered direct offering were filed with the SEC and are available at the SEC's website at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the registered direct offering may also be obtained by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (212) 856-5711 or e-mail at placements@hcwco.com.</p>
<div class="lb-trans"><p>普通股（或预先融资认股权证）（但不包括在私募中发行的短期认股权证或其所对应的普通股）是根据公司于 2025 年 7 月 9 日向证券交易委员会（&#34;SEC&#34;）提交的&#34;货架&#34;注册声明（文件编号：333-288595）进行发行，并于 2026 年 1 月 6 日生效。普通股（或预先融资认股权证）的注册直接发行仅通过招股说明书进行，包括构成有效注册声明一部分的招股说明书补充。与注册直接发行相关的招股说明书补充及随附的招股说明书已向 SEC 提交，并可在 SEC 网站 www.sec.gov 上获取。与注册直接发行相关的招股说明书补充及随附的招股说明书的电子副本也可通过联系 H.C. Wainwright &amp; Co., LLC，地址为 430 Park Avenue, 3rd Floor, New York, NY 10022，电话 (212) 856-5711 或电子邮件 placements@hcwco.com 获取。</p>
</div><p>The short-term warrants described above were issued in a concurrent private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &#34;Securities Act&#34;), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the short-term warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the short-term warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.</p>
<div class="lb-trans"><p>上述短期认股权证是在根据 1933 年证券法（&#34;证券法&#34;）第 4(a)(2) 条及其下的 D 条款进行的同时私募中发行的，并且与短期认股权证所对应的普通股一起，未根据证券法或适用的州证券法进行注册。因此，短期认股权证及其所对应的普通股在美国不得提供或出售，除非根据有效的注册声明或适用的证券法的注册要求的豁免。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售或招揽购买此处描述的任何证券的要约，也不应在任何州或司法管辖区进行这些证券的销售，除非在任何此类州或司法管辖区的证券法下进行注册或资格认证。</p>
</div><p><strong>About Acurx Pharmaceuticals, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Acurx Pharmaceuticals, Inc.</strong></p>
</div><p>Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&amp;D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).</p>
<div class="lb-trans"><p>Acurx Pharmaceuticals 是一家处于后期阶段的生物制药公司，专注于开发新型小分子抗生素以治疗难以治疗的细菌感染。公司的方法是开发具有革兰氏阳性选择性谱（GPSS®）的抗生素候选药物，阻断革兰氏阳性特异性细菌酶 DNA 聚合酶 IIIC（pol IIIC）的活性位点，抑制 DNA 复制并导致革兰氏阳性细菌细胞死亡。其研发管线包括针对革兰氏阳性细菌的抗生素产品候选药物，包括艰难梭菌、耐甲氧西林金黄色葡萄球菌（MRSA）、耐万古霉素肠球菌（VRE）、耐药性肺炎链球菌（DRSP）和炭疽杆菌（炭疽；生物恐怖主义 A 类威胁级病原体）。</p>
</div><p>Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection (CDI) is Phase 3 ready to advance to international clinical trials subject to obtaining appropriate financing. The Company recently announced the launch of a ground-breaking clinical trial with ibezapolstat in patients with multiply-recurrent CDI (rCDI) that has the potential to shift the paradigm of treatment and prevention of rCDI from two agents to one. This new clinical trial in rCDI begins with an open-label pilot trial to gain experience with IBZ in patients with multiply-recurrent CDI with at least 3 episodes of CDI within the past 12 months. This will inform elements of a planned active-controlled, Phase 3 registration trial in the rCDI indication to be implemented following favorable results from the open-label 20 patient trial. Upon subsequent successful completion of the Ph3 pivotal rCDI trial, and per the operative FDA procedure, Acurx plans to request FDA approval for treatment and prevention of rCDI under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (Guidance for Industry, 2020).</p>
<div class="lb-trans"><p>Acurx 的主要产品候选药物 ibezapolstat 用于治疗艰难梭菌感染（CDI），已准备进入第三阶段国际临床试验，前提是获得适当的融资。公司最近宣布启动一项开创性的临床试验，使用 ibezapolstat 治疗多次复发的 CDI（rCDI），这有可能将 rCDI 的治疗和预防范式从两种药物转变为一种药物。该 rCDI 的新临床试验将以开放标签的试点试验开始，以获取在过去 12 个月内至少有 3 次 CDI 发作的多次复发 CDI 患者中使用 IBZ 的经验。这将为计划中的 rCDI 适应症的主动对照第三阶段注册试验提供信息，该试验将在开放标签 20 名患者试验获得良好结果后实施。在随后成功完成 Ph3 关键 rCDI 试验后，根据 FDA 的操作程序，Acurx 计划请求 FDA 批准用于 rCDI 的治疗和预防，依据 FDA 的抗菌和抗真菌药物有限人群途径（行业指南，2020 年）。</p>
</div><p>The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel.</p>
<div class="lb-trans"><p>公司的临床前管线包括开发一种用于治疗急性细菌性皮肤和皮肤结构感染（ABSSSI）的口服产品候选药物，同时正在计划一项用于治疗吸入性炭疽的开发项目。</p>
</div><p>To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.</p>
<div class="lb-trans"><p>要了解更多关于 Acurx Pharmaceuticals 及其产品管线的信息，请访问 www.acurxpharma.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words &#34;believes,&#34; &#34;anticipates,&#34; &#34;plans,&#34; &#34;expects,&#34; and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the exercise of the short-term warrants prior to their expiration and the use of proceeds from the offering. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: market and other conditions, and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2025, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward-looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.</p>
<div class="lb-trans"><p>本新闻稿中关于我们未来预期、计划和前景的任何声明，包括关于我们的战略、未来运营、前景、计划和目标的声明，以及包含 “相信”、“预期”、“计划”、“期望” 和类似表达的其他声明，构成 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明。前瞻性声明包括关于在短期认股权证到期前行使的声明以及从发行中获得的收益的使用。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有实质性差异，包括市场和其他条件，以及在公司向证券交易委员会提交的 2025 年 12 月 31 日结束的 10-K 表格年度报告中描述的其他风险和不确定性，以及公司随后向证券交易委员会提交的文件。这些前瞻性声明仅在本新闻稿日期有效，Acurx 不承担更新这些前瞻性声明以反映该声明日期后事件或情况的意图或义务，除非法律要求。</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>Acurx Pharmaceuticals, Inc.</p>
<div class="lb-trans"><p>Acurx Pharmaceuticals, Inc.</p>
</div><p>David P. Luci, President &amp; Chief Executive Officer</p>
<div class="lb-trans"><p>David P. Luci，总裁兼首席执行官</p>
</div><p>Tel: 917-533-1469</p>
<div class="lb-trans"><p>电话：917-533-1469</p>
</div><p>Email: davidluci@acurxpharma.com</p>
<div class="lb-trans"><p>电子邮件：davidluci@acurxpharma.com</p>
</div><p>SOURCE Acurx Pharmaceuticals, Inc.</p>
<div class="lb-trans"><p>来源：Acurx Pharmaceuticals, Inc.</p>
</div>

Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | ACXP Stock News

StockTitan

Acurx Pharmaceuticals

纳斯达克 OMX 交易所

Acurx Pharmaceuticals, Inc. 宣布根据纳斯达克规则以市场价格完成高达 710 万美元的注册直接发行 | ACXP 股票新闻